10-Q: Cosmos Health Reports Q2 2026 Results, Faces Going Concern Doubt

Cosmos Health Inc. reported increased revenue for the six months ended June 30, 2026, but also a significant net loss and substantial doubt about its ability to continue as a going concern.

Summary

• Cosmos Health Inc. reported revenue of $36.9 million for the first six months of 2026, a 29.7% increase year-over-year, driven by growth in its wholesale, manufacturing, and nutraceutical businesses.
• However, the company incurred a net loss of $8.9 million for the same period, a significant increase from $3.6 million in the prior year, largely due to non-cash items like convertible note fair value changes and digital asset losses.
• The company's financial statements indicate substantial doubt about its ability to continue as a going concern, citing insufficient revenue to cover operating expenses and debt obligations, and a reliance on external financing.
• Operating expenses increased by 19.6% to $8.0 million for the six-month period, primarily due to higher administrative and investor relations costs.
• The company raised approximately $2.9 million through its At-the-Market (ATM) program during the quarter to enhance liquidity.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant net loss, increased operating expenses, and the ongoing substantial doubt about the company's ability to continue as a going concern, despite revenue growth.

Positives

• Revenue increased by 29.7% to $36.9 million for the six months ended June 30, 2026, compared to the same period in 2025.
• Gross profit for the three months ended June 30, 2026, increased by 29.9% to $1.5 million, with a gross margin of 8.0%.
• The company's wholesale subsidiary, Decahedron Ltd, nearly doubled its revenue.
• Cana, the pharmaceutical manufacturing subsidiary, expanded contract manufacturing agreements, leading to a material revenue increase.
• Cosmofarm S.A., the wholesale subsidiary, added over 75 new pharmacies to its client portfolio.
• SkyPharm SA expanded the distribution of its Sky Premium Life brand in the UAE, Cyprus, and Greece.
• The company raised approximately $2.9 million through its At-the-Market (ATM) program during the quarter.

Negatives

• Net loss for the six months ended June 30, 2026, increased by 143.9% to $8.9 million compared to $3.6 million in the prior year.
• Operating expenses increased by 19.6% to $8.0 million for the six-month period.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company experienced a significant increase in non-cash items, including a $2.14 million loss from the change in fair value of convertible notes and a $0.85 million loss on digital assets.
• Gross profit for the six months ended June 30, 2026, decreased by 10.0% to $2.9 million, with gross margin falling to 7.8% from 11.3% due to revenue reversals related to Medihelm.
• The company reported a foreign currency translation loss of $351,421 for the six months ended June 30, 2026, compared to a gain of $2,593,738 in the prior year.

Risks

• Substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.
• The Company remains dependent on external financing sources to sustain operations and fund growth initiatives.
• If the Company is unable to obtain funding, it could be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization efforts.
• The Company is subject to risks associated with substantial expenditures for research and development, with no assurance that projects will be successful or that products will obtain regulatory approval or be commercially viable.
• Supply chain disruptions and volatility in the availability and cost of materials or services are ongoing concerns.
• The Company's financial statements indicate material weaknesses in internal controls over financial reporting, including inadequate supervision, segregation of duties, and IT general controls.

Future Outlook

The company plans to expand its product portfolio, launch new distribution channels, and increase sales from secured agreements, particularly in the UAE. It also intends to expand its customer base for its wholesale subsidiary and strengthen contract manufacturing agreements for its manufacturing subsidiary. Financially, the company plans to continue and potentially expand its At-the-Market (ATM) program and may enter into new convertible financing arrangements to support future liquidity needs.

Management Comments

• Management has evaluated these factors and its ability to meet obligations due within the next 12 months. Its plans include expanding the portfolio of brand name and private label products, launching new distribution channels, and increasing sales from recently secured agreements, such as the exclusive distribution of Sky Premium Life products in the United Arab Emirates (UAE).
• Considering the Companys significant net loss and negative operating cash flows for the reporting period, management has concluded that substantial doubt exists about the Companys ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.

Industry Context

StockSavvy.ai notes that Cosmos Health operates in the competitive pharmaceutical and nutraceutical sectors, facing challenges common to the industry, including supply chain disruptions, pricing pressures, and regulatory hurdles. The company's strategy of vertical integration and R&D investment aims to differentiate itself, but the current financial performance raises concerns about its ability to execute these plans effectively.

Legal Proceedings

• Cana Laboratories SA v. Evangelismos Hospital (Case No. 1225/2023): Lawsuit seeking recovery of approximately $248,382 plus accrued interest for unpaid invoices; hearing postponed to May 19, 2026.
• SkyPharm S.A. received corrective tax assessments from Greek tax authorities for fiscal years 2017-2018 and VAT for 2018, aggregating approximately $1,100,464 plus statutory interest; the company has appealed these assessments.

Related Party Transactions

• Prepaid expenses and other current assets - related party balance to Doc Pharma S.A. of $4.3 million as of June 30, 2026, with a reserve of $103,771.
• Accounts payable and accrued expenses - related party balance to Doc Pharma S.A. of $357,294 as of June 30, 2026.
• Accounts receivable - related party balance from Doc Pharma S.A. of $3.2 million as of June 30, 2026, with a reserve of $1.5 million.
• Sales to Doc Pharma S.A. totaled $30,631 for the three months ended June 30, 2026.
• Purchases from Doc Pharma S.A. totaled $171,806 for the three months ended June 30, 2026.
• Prepaid salaries to Grigorios Siokas (CEO) of $885,281 as of June 30, 2026.
• Unpaid salaries and bonuses due to George Terzis (CFO) of $438,000 as of June 30, 2026.

Stakeholder Impact

• Shareholders may be concerned about the company's going concern status and the dilution from potential future capital raises.
• Creditors and lenders may face increased risk due to the company's net losses and reliance on external financing.
• Employees may be concerned about job security given the company's financial performance and the ongoing remediation of internal control weaknesses.

Next Steps

• Expand the portfolio of brand name and private label products.
• Launch new distribution channels.
• Increase sales from recently secured agreements, such as the exclusive distribution of Sky Premium Life products in the UAE.
• Expand the customer base of its subsidiary, Cosmofarm S.A.
• Strengthen existing contract manufacturing agreements and secure new ones for its manufacturing subsidiary, CANA S.A.
• Continue and potentially expand its At-the-Market (ATM) program.
• Enter into new convertible financing arrangements.

Key Dates

Recommendation

The company's significant net loss, increasing operating expenses, and the explicit statement of substantial doubt about its ability to continue as a going concern, despite revenue growth, present a high-risk investment profile. The reliance on future financing and the ongoing remediation of internal control weaknesses further amplify these concerns, suggesting a sell recommendation for seasoned investors.

Keywords

Cosmos Health, Form 10-Q, Quarterly Report, Financial Statements, Revenue Growth, Net Loss, Going Concern, Convertible Notes